





Drospirenone Containing Oral Contraceptives Drug Use Criteria

Created: October 2014

Reviewed: September 2015, April 2019

Includes:

| Yaz© | Ethinyl Estradiol and Drospirenone |
|------------------|------------------------------------|
| Yasmin © | Ethinyl Estradiol and Drospirenone |
| Zarah © | Ethinyl Estradiol and Drospirenone |
| Vestura © | Ethinyl Estradiol and Drospirenone |
| Syeda© | Ethinyl Estradiol and Drospirenone |
| Ocella © | Ethinyl Estradiol and Drospirenone |
| Nikki© | Ethinyl Estradiol and Drospirenone |
| Loryna© | Ethinyl Estradiol and Drospirenone |
| Gianvi © | Ethinyl Estradiol and Drospirenone |

^{**}or any other brand or generic formulation of oral contraceptive containing drospirenone.

Guideline for Use:

- 1. Is the patient being treated for a funded condition by Oregon Health Plan?
 - a. If yes, go to 2
 - b. If no, deny as Below the Funded Line for Oregon Health Plan.
- 2. Does the patient have Polycystic Ovary Syndrome (PCOS) supported in the chart notes submitted for review?
 - a. If yes, approve for 12 fills.
 - b. If no, go to 3
- 3. Does the patient have Premenstrual Dysphoric Disorder (PMDD) supported in the chart notes submitted for review?
 - a. If yes, approve for 12 fills.
 - b. If no, deny as not meeting criteria. Please use formulary alternative.


Rationale:

Drospirenone containing oral contraceptives have been associated with an increased risk of thromboembolic events; therefore, in order to ensure the safest and most cost-effective oral contraceptive preparations are utilized for Advanced Health members, the above drug use criteria was developed. Acne must meet Guideline Note 132: Acne Conglobata and Acne Fulminans or Guideline Note 65: Severe Cystic Acne of the Prioritized List of Health Services to be considered a covered comorbid condition.

FDA Approved Indications: Indicated for the prevention of pregnancy, treatment of PMDD, and treatment of acne.

Approved by DOCS/WOAH Pharmacy and Therapeutics Committee on 10/27/2014

Approved by Advanced Health Pharmacy and Therapeutics Committee on 4/22/2019, 01/22/2020



Phone: 541-269-7400 Fax: 541-269-7789



References:

UpToDate. Ethinyl Estradiol and Drospirenone: Drug Information. October 2014.
Health Evidence Review Commission Prioritized List of Health Services. Guideline Note 132: Acne
Conglobata and Acne Fulminans and Guideline Note 65: Severe Cystic Acne. January 1, 2020 Prioritized
List.